Ovii

Meet Enveda

Enveda is a clinical-stage biotechnology company developing small-molecule medicines by combining artificial intelligence, metabolomics, mass spectrometry and automated laboratory workflows with chemistry found in living organisms. Its PRISM platform analyzes large-scale chemical data to identify previously unexplored molecules and connect them with biological activity, enabling Enveda to select and develop drug candidates. The company has advanced multiple oral medicines into clinical development, including programs for inflammatory and metabolic diseases. Enveda operates major research and development facilities in Boulder, Colorado and Hyderabad, India, combining computational drug discovery, chemistry, biology and clinical development within one organization.View more

Enveda is a clinical-stage biotechnology company developing small-molecule medicines by combining artificial intelligence, metabolomics, mass spectrometry and automated laboratory workflows with chemistry found in living organisms. Its PRISM platform analyzes large-scale chemical data to identify previously unexplored molecules and connect them with biological activity, enabling Enveda to select and develop drug candidates. The company has advanced multiple oral medicines into clinical development, including programs for inflammatory and metabolic diseases. Enveda operates major research and development facilities in Boulder, Colorado and Hyderabad, India, combining computational drug discovery, chemistry, biology and clinical development within one organization.

Founded
2019
Company size
201-500 employees
Company stage
Not known
Headquarters
Boulder, USA

Why work here

Enveda combines software, AI, mass spectrometry, laboratory automation and clinical drug development, giving candidates opportunities to work across unusually interdisciplinary technical and scientific problems. The company raised a $311 million Series E in 2026, bringing total capital raised to more than $845 million, and has advanced multiple oral medicines into human trials with positive early clinical readouts. Current engineering roles use technologies including Python, FastAPI, Vue 3, TypeScript, Databricks, Prefect and Azure. Enveda's careers materials list flexible PTO, a company-wide year-end break, 12 weeks of paid parental leave and a work-from-home stipend. Many laboratory and scientific roles are on-site in Boulder or Hyderabad, reflecting the hands-on nature of its research.Read more

Enveda combines software, AI, mass spectrometry, laboratory automation and clinical drug development, giving candidates opportunities to work across unusually interdisciplinary technical and scientific problems. The company raised a $311 million Series E in 2026, bringing total capital raised to more than $845 million, and has advanced multiple oral medicines into human trials with positive early clinical readouts. Current engineering roles use technologies including Python, FastAPI, Vue 3, TypeScript, Databricks, Prefect and Azure. Enveda's careers materials list flexible PTO, a company-wide year-end break, 12 weeks of paid parental leave and a work-from-home stipend. Many laboratory and scientific roles are on-site in Boulder or Hyderabad, reflecting the hands-on nature of its research.

Industry
Biotechnology / AI Drug Discovery
Open jobs
12 open jobs
Notable investors
Catalio Capital Management, Lightspeed Venture Partners, ICONIQ, Premji Invest, Kinnevik, Baillie Gifford, FPV Ventures, True Ventures, Lux Capital, Dimension

Tech stack

Python

Programming Language

FastAPI

Backend Framework

Vue 3

Frontend Framework

TypeScript

Programming Language

Databricks

Data Platform

Delta Lake

Data Lake

SQL

Data Query Language

Prefect

Workflow Orchestration

Microsoft Azure

Cloud Platform

Benchling

Scientific Data Platform

CDD Vault

Scientific Data Platform

Anthropic Claude

AI Model

Key people

8 people
Viswa ColluruCo-founderView bio

Founder and CEO of Enveda. Colluru previously served as the first Innovation Scientist and Product Manager at Recursion, where he also established its Portfolio/Early Commercial team. He earned a PhD in immuno-oncology and cellular and molecular biology at the University of Wisconsin-Madison and has more than a decade of experience in translational biomedical discovery.

LinkedIn
Pieter DorresteinCo-founderView bio

Scientific Co-Founder of Enveda and a professor at UC San Diego. Dorrestein specializes in mass spectrometry, metabolomics, natural-product chemistry and molecular networking. He earned a PhD in Chemical Biology from Cornell University and has developed widely used approaches for analyzing the chemical diversity of biological systems.

LinkedIn
August AllenChief Technology OfficerView bio

Chief Technology Officer overseeing Enveda's technology platform for identifying the structure and function of molecules from nature. Allen previously worked at Recursion, where he helped scale its high-content imaging platform, and joined Enveda in 2021. His work spans laboratory automation, software and high-throughput biotechnology.

LinkedIn
Hannah GordonChief Scientific OfficerView bio

Chief Scientific Officer responsible for scientific strategy and translational drug discovery. Gordon has more than a decade of biotechnology experience, including at Recursion. She holds a PhD in Human Genetics and an MS in Clinical Investigation from the University of Utah, with expertise spanning translational biology and technology-enabled drug discovery.

LinkedIn
View all 8 people
Niranjan RaoChief Development OfficerView bio

Chief Development Officer overseeing advancement of Enveda's programs through clinical development. Rao previously held senior development roles at Asana BioSciences, Endo Pharmaceuticals, Kyowa Hakko Kirin, Forest Laboratories and Aventis. He is a clinical pharmacologist and a Fellow of the American College of Clinical Pharmacology.

LinkedIn
Jason KimChief Financial OfficerView bio

Chief Financial Officer responsible for Enveda's financial strategy, operations and growth. Kim previously served as President, COO and CFO of Molecular Templates and held roles at ImClone Systems, OSI Pharmaceuticals, Domain Associates and Safeguard Scientifics. He earned an MBA from Wharton and a BA in Neuroscience from Wesleyan University.

Inhwan KimChief Strategy OfficerView bio

Chief Strategy Officer helping shape Enveda's pipeline, portfolio strategy and long-term company direction. Kim previously managed portfolio strategy at BridgeBio and worked at McKinsey advising biotechnology, pharmaceutical and public-health organizations. He holds a PharmD from Rutgers University and an MBA from Northwestern University's Kellogg School of Management.

LinkedIn
Robert BuckleyChief People OfficerView bio

Chief People Officer leading Enveda's people and talent organization. Buckley previously served as Chief People Officer at RainFocus and held HR leadership roles at Thumbtack, eBay and GE Healthcare. His experience includes building and scaling global workforces across technology and healthcare organizations.

LinkedIn

Latest company news

4 stories

Enveda Collaborates with Anthropic to Accelerate Drug Development

Enveda

Enveda reported using Anthropic's Claude models in AI-assisted workflows for pharmaceutical manufacturing and regulatory documentation, including batch-record review and preparation of regulatory content while retaining expert oversight and quality controls.

Read article

Enveda Raises $311 Million From Leading AI and Biotech Investors

Enveda

Enveda closed a $311 million Series E led by Catalio Capital Management, bringing total capital raised since inception to more than $845 million. The funding is intended to advance its clinical pipeline and expand its PRISM discovery platform and automated laboratory.

Read article

Enveda Reports Positive Phase 1 Results for ENV-308

Enveda

Enveda reported Phase 1 results for ENV-308, an investigational oral medicine inspired by the exercise-associated metabolite Lac-Phe. The study enrolled 88 healthy volunteers, and the company outlined plans for additional trials related to metabolic health and weight maintenance.

Read article

Enveda Reports Positive Results for ENV-294 in a Phase 1b Clinical Trial

Enveda

Enveda announced positive Phase 1b results for ENV-294, its investigational once-daily oral therapy for moderate-to-severe atopic dermatitis, providing early clinical validation for a medicine discovered through its chemistry-first platform.

Read article

Jobs at Enveda

12 open roles